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Atypical haemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G) are 
associated with dysregulation of the alternative pathway (AP) of complement. Recently, 
we described an updated compilation of 324 genetic variants identified in four AP genes 
encoding the proteins factor H (FH), factor I (FI), membrane cofactor protein (MCP, CD46) 
and C3 in our interactive FH-HUS web-database (www.fh-hus.org). Our database has 
been updated further to a new version, the ‘Database of Complement Gene Variants’ 
(www.complement-db.org), with variant data contributed by six centres (Newcastle, Paris, 
Bergamo, Madrid, Iowa City, and Nijmegen) from >1000 patients with aHUS and C3G. 
This laboratory dataset comprises 601 variants (allele frequency < 1%) in 13 genes (CFH, 
CFI, CD46, C3, CFB, CFHR1, CFHR3, CFHR5, CFP, PLG, DGKE, THBD, ADAMTS13). 
The database provides enhanced search tools and the ability to assess variant 
pathogenicity using:  
 Comparison of the estimated disease-associated variant allele frequencies to those 
of matched variants in 3 control datasets, namely “The 1000 Genomes Project,” the 
“ExAC” and the “Exome Variant Server (EVS)” using Chi-square analyses. 
 The mapping of missense variants onto protein structural models.  
 Determination of the pathogenicity of each variant from its residue position, amino 
acid property, binding sites and residue conservation using PolyPhen-2, PROVEAN 
and SIFT.   
 Measurement of the degree to which amino acid properties at any residue position 
are conserved across evolution, both within humans, and across other species, by 
multiple sequence alignment methods. 
Thus, the tools in this new version of the database enable us to identify rare variants of 
the complement proteins enriched in disease which are worthy of further functional 
analysis. We will describe their occurrence in these 13 proteins, and discuss the utility of 
this new database for characterising complement-mediated diseases. 
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